P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs

Abstract

Ticagrelor is more efficient than clopidogrel in attenuating myocardial structural and functional alterations post-MI and in improving cardiac healing. These benefits are associated with persistent AMPK and Akt/PKB activation.

Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans

“…This is of potential interest as there is evidence for adenosineinduced protection against ischemia-reperfusion injury 139,140 . In fact, ticagrelor has been shown to confer cardioprotection in animal studies of ischemia-reperfusion in an adenosinedependent manner [141][142][143][144] . Whether ticagrelor protects against ischemia-reperfusion injury in humans has not been investigated previously.…”

Overexpression of lncRNA Gm2691 attenuates apoptosis and inflammatory response after myocardial infarction through PI3K/Akt signaling pathway

“…In previous studies, Akt signaling pathway has been shown to play an important role in I/R injury . We wonder whether lncRNA Gm2691 regulate the Akt signaling pathway.…”

“…In previous studies, Akt signaling pathway has been shown to play an important role in I/R injury. 23 We wonder whether lncRNA Gm2691 regulate the Akt signaling pathway. Western blot analysis was performed to examine whether p-Akt and p-ERK1/2 pathways were regulated by lncRNA Gm2691.…”

Ticagrelor Prevents Endothelial Cell Apoptosis through the Adenosine Signalling Pathway in the Early Stages of Hypoxia

“…Numerous experimental and clinical studies have suggested that P2Y12 receptor antagonists can directly reduce the size of the myocardial infarction [10][11][12][13]17,26,31,32]. In animal models of acute I/R, ticagrelor, and cangrelor, administered a few minutes before reperfusion, significantly reduced the size of the myocardial infarction [10,12,[15][16][17].…”

“…Therefore, pharmacological-induced protection against vascular endothelial apoptosis may limit the development of ischaemic lesions of different organs, particularly at the cardiac, renal, and neurological levels [2,3,6]. Several publications have reported the beneficial effects of P2Y12 receptor antagonists (e.g., clopidogrel, prasugrel, cangrelor, and ticagrelor) in cardioprotection against ischaemia-reperfusion injuries [7][8][9][10][11][12][13][14][15][16][17]. First, the beneficial effects of antiplatelet agents have been attributed to a decrease in platelet aggregation and, indirectly, intravascular coagulation, thus preventing coronary thrombotic re-occlusion.…”